RVMD
The table below shows Revolution Medicines, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $11.58M | $35.38M | $29.39M | $42.98M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $987.33M | $592.23M | $423.14M | $253.07M | $186.95M | $132.25M |
| SG&A |
Revolution Medicines, Inc. reported annual revenue of $0.00 for fiscal year 2025. Over the 8 fiscal years shown, annual revenue declined from $20.16M (FY 2018) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $195.04M |
| $97.30M |
| $75.62M |
| $40.59M |
| $30.45M |
| $21.43M |
| Operating income | -$1.18B | -$689.52M | -$487.19M | -$258.28M | -$188.01M | -$110.70M |
| Income tax | $0.00 | -$753.00K | -$3.52M | -$420.00K | $0.00 | -$371.00K |
| Net income | -$1.13B | -$600.00M | -$436.00M | -$249.00M | -$187.00M | -$108.16M |
| EPS (diluted) | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 |